Abstract
Background
Aberrant kallikrein activity is observed in a number of inflammatory dermatoses. Up-regulation of kallikrein-5 (KLK5) activity leads to uncontrolled skin desquamation and cleavage of proteinase-activated receptor-2 (PAR2), causing the release of pro-inflammatory cytokines and disruption of epidermal barrier function. This study aimed to identify KLK5-specific small molecule inhibitors which can serve as the foundation of a novel therapeutic for inflammatory skin disorders.
Methods
Five chemical libraries (13,569 compounds total) were screened against recombinant KLK5 using a fluorogenic enzymatic assay. Secondary validation was performed on the top 22 primary hits. All hits were docked in the KLK5 crystal structure to rationalize their potential interactions with the protein.
Results
A naturally occurring compound derived from the wood of Caesalpinia sappan (Brazilin) was identified as a novel KLK5 inhibitor (IC50: 20 μM, Ki: 6.4 μM). Docking suggests that the phenolic moiety of Brazilin binds in the S1-pocket of KLK5 and forms a H-bond with S195 side chain. KLK14 was also found to be susceptible to inhibition by Brazilin with a calculated IC50 value of 14.6 μM.
Conclusions
Natural KLK5 small molecule inhibitors such as Brazilin, are ideal for topical skin disease drug design and remain a promising therapeutic for severe cases of inflammatory skin disorders. Optimized KLK inhibitors may have increased efficacy as therapeutics and warrant further investigation.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009;284:32989–94.10.1074/jbc.R109.027946Search in Google Scholar PubMed PubMed Central
2. Komatsu N, Saijoh K, Toyama T, Ohka R, Otsuki N, Hussack G, et al. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Brit J Derm 2005;153:274–81.10.1111/j.1365-2133.2005.06754.xSearch in Google Scholar PubMed
3. Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 2005;124:198–203.10.1111/j.0022-202X.2004.23547.xSearch in Google Scholar PubMed
4. Sakabe J, Yamamoto M, Hirakawa S, Motoyama A, Ohta I, Tatsuno K, et al. Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes. J Biol Chem 2013;288:17179–89.10.1074/jbc.M113.476820Search in Google Scholar PubMed PubMed Central
5. Bonnart C, Deraison C, Lacroix M, Uchida Y, Besson C, Robin A, et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J Clin Invest 2010;120:871–82.10.1172/JCI41440Search in Google Scholar PubMed PubMed Central
6. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006;20:2068–80.10.1096/fj.06-6075comSearch in Google Scholar PubMed
7. Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 2004;122:1235–44.10.1111/j.0022-202X.2004.22512.xSearch in Google Scholar PubMed
8. Borgoño CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, et al. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem 2007;282:3640–52.10.1074/jbc.M607567200Search in Google Scholar PubMed
9. Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell 2007;18:3607–19.10.1091/mbc.e07-02-0124Search in Google Scholar PubMed PubMed Central
10. Egelrud T, Brattsand M, Kreutzmann P, Walden M, Vitzithum K, Marx UC, et al. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Brit J Dermatol 2005;153:510–20.10.1111/j.1365-2133.2005.06834.xSearch in Google Scholar PubMed
11. Hachem JP, Man MQ, Crumrine D, Uchida Y, Brown BE, Rogiers V, et al. Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol 2005;125:510–20.10.1111/j.0022-202X.2005.23838.xSearch in Google Scholar PubMed
12. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, et al. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. J Invest Dermatol 2006;126:2338–42.10.1038/sj.jid.5700379Search in Google Scholar PubMed
13. Komatsu N, Saijoh K, Kuk C, Shirasaki F, Takehara K, Diamandis EP. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. Brit J Dermatol 2007;156:875–83.10.1111/j.1365-2133.2006.07743.xSearch in Google Scholar PubMed
14. Yamasaki K, Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature Med 2007;13:975–80.10.1038/nm1616Search in Google Scholar PubMed
15. Voegeli R, Rawlings AV, Breternitz M, Doppler S, Schreier T, Fluhr JW. Increased stratum corneum serine protease activity in acute eczematous atopic skin. Brit J Dermatol 2009;161:70–7.10.1111/j.1365-2133.2009.09142.xSearch in Google Scholar PubMed
16. Hollenberg MD, Oikonomopoulou K, Hansen KK, Saifeddine M, Ramachandran R, Diamandis EP. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Biol Chem 2008;389:643–51.10.1515/BC.2008.077Search in Google Scholar PubMed
17. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, Blaber M, et al. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem 2006;387:817–24.10.1515/BC.2006.104Search in Google Scholar PubMed
18. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000;25:141–2.10.1038/75977Search in Google Scholar PubMed
19. Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res 2013;351:289–300.10.1007/s00441-013-1558-1Search in Google Scholar PubMed
20. Furio L, de Veer S, Jaillet M, Briot A, Robin A, Deraison C, et al. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome. J Exp Med 2014;211:499–513.10.1084/jem.20131797Search in Google Scholar PubMed PubMed Central
21. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, et al. Kallikrein 5 induces atopic dermatitis–like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 2009;206:1135–47.10.1084/jem.20082242Search in Google Scholar PubMed PubMed Central
22. Stefansson K, Brattsand M, Roosterman D, Kempkes C, Bocheva G, Steinhoff M, et al. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J Invest Dermatol 2008;128:18–25.10.1038/sj.jid.5700965Search in Google Scholar PubMed
23. Prassas I, Eissa A, Poda G, Diamandis EP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov 2015;14:183–202.10.1038/nrd4534Search in Google Scholar PubMed
24. Yu Y, Prassas I, Dimitromanolakis A, Diamandis EP. Novel biological substrates of human kallikrein 7 identified through degradomics. J Biol Chem 2015;290:17762–75.10.1074/jbc.M115.643551Search in Google Scholar PubMed PubMed Central
25. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007;53:1423–32.10.1373/clinchem.2007.088104Search in Google Scholar PubMed
26. Richardson JL, Nett IR, Jones DC, Abdille MH, Gilbert IH, Fairlamb AH. Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis. Chem Med Chem 2009;4:1333–40.10.1002/cmdc.200900097Search in Google Scholar PubMed PubMed Central
27. Miyahara K, Kawasaki T, Kinjyo J-E, Shimokawa T, Yamahara J, Yamasaki M, et al. The X-ray analysis of caesalpin J from sappan lignum. Chem Pharm Bull 1986;34:4166–9.10.1248/cpb.34.4166Search in Google Scholar PubMed
28. Debela M, Goettig P, Magdolen V, Huber R, Schechter NM, Bode W. Structural basis of the zinc inhibition of human tissue kallikrein 5. J Mol Biol 2007;373:1017–31.10.1016/j.jmb.2007.08.042Search in Google Scholar PubMed
29. Gooderham M, Lynde CW, Papp K, Bourcier M, Guenther L, Gulliver W, et al. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg 2017;21:31–9.10.1177/1203475416670364Search in Google Scholar PubMed
30. Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol 2005;53:S3–16.10.1016/j.jaad.2005.04.026Search in Google Scholar PubMed
31. Chen W, Kinsler VA, Macmillan D, Di WL. Tissue kallikrein inhibitors based on the sunflower trypsin inhibitor scaffold – a potential therapeutic intervention for skin diseases. PLoS One 2016;11:e0166268.10.1371/journal.pone.0166268Search in Google Scholar PubMed PubMed Central
32. de Veer SJ, Furio L, Swedberg JE, Munro CA, Brattsand M, Clements JA, et al. Selective substrates and inhibitors for kallikrein-related peptidase 7 (KLK7) shed light on KLK proteolytic activity in the stratum corneum. J Invest Dermatol 2017;137:430–9.10.1016/j.jid.2016.09.017Search in Google Scholar PubMed
33. Tan X, Soualmia F, Furio L, Renard J-F, Kempen I, Qin L, et al. Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Biol Chem 2015;58:598–612.10.1021/jm500988dSearch in Google Scholar PubMed
34. Rondão R, de Melo SJ, Pina J, Mello MJ, Vitorino T, Parola AJ. Brazilwood reds: the (photo) chemistry of brazilin and brazilein. J Phys Chem 2013;117:10650–60.10.1021/jp404789fSearch in Google Scholar PubMed
35. Działo M, Mierziak J, Korzun U, Preisner M, Szopa J, Kulma A. The potential of plant phenolics in prevention and therapy of skin disorders. Inter J Mol Sci 2016;17:160.10.3390/ijms17020160Search in Google Scholar PubMed PubMed Central
36. Nirmal NP, Rajput MS, Prasad R, Ahmad M. Brazilin from Caesalpinia sappan heartwood and its pharmacological activities: a review. Asian Pac J Trop Med 2015;8:421–30.10.1016/j.apjtm.2015.05.014Search in Google Scholar PubMed
37. Nirmal N, Panichayupakaranant P. Antioxidant, antibacterial, and anti-inflammatory activities of standardized brazilin-rich Caesalpinia sappan extract. Pharm Biol 2015;53:1339–43.10.3109/13880209.2014.982295Search in Google Scholar PubMed
38. Batubara I, Mitsunaga T, Ohashi H. Brazilin from Caesalpinia sappan wood as an antiacne agent. J Wood Sci 2010;56:77–81.10.1007/s10086-009-1046-0Search in Google Scholar
39. Washiyama M, Sasaki Y, Hosokawa T, Nagumo S. Anti-inflammatory constituents of Sappan Lignum. Biol Pharm Bull 2009;32:941–4.10.1248/bpb.32.941Search in Google Scholar PubMed
40. Li ZY, Zheng Y, Chen Y, Pan M, Zheng SB, Huang W, et al. Brazilin ameliorates diabetic nephropathy and inflammation in db/db mice. Inflammation 2017;40:1365–74.10.1007/s10753-017-0579-4Search in Google Scholar PubMed
41. Jung M, Hur D, Song S, Park Y, Kim T, Bang S, et al. Tannic acid and quercetin display a therapeutic effect in atopic dermatitis via suppression of angiogenesis and TARC expression in Nc/Nga mice. J Invest Dermatol 2010;130:1459–63.10.1038/jid.2009.401Search in Google Scholar PubMed
42. Nirmal N, Panichayupakaranant P. Anti-Propionibacterium acnes assay-guided purification of brazilin and preparation of brazilin rich extract from Caesalpinia sappan heartwood. Pharm Biol 2014;52:1204–7.10.3109/13880209.2014.884607Search in Google Scholar PubMed
43. Stefansson K, Brattsand M, Ny A, Glas B, Egelrud T. Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum. Biol Chem 2006;367:3031–41.10.1515/BC.2006.095Search in Google Scholar PubMed
44. Emami N, Diamandis EP. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade possible function in seminal plasma and skin. J Biol Chem 2008;283:3031–41.10.1074/jbc.M707253200Search in Google Scholar PubMed
45. Kasparek P, Ileninova Z, Zbodakova O, Kanchev I, Benada O, Chalupsky K, et al. KLK5 and KLK7 ablation fully rescues lethality of Netherton syndrome-like phenotype. PLoS Genet 2017;13:e1006566.10.1371/journal.pgen.1006566Search in Google Scholar PubMed PubMed Central
46. Matsubara Y, Matsumoto T, Koseki J, Kaneko A, Aiba S, Yamasaki K. Inhibition of human kallikrein 5 protease by triterpenoids from natural sources. Molecules 2017;22:1–12.10.3390/molecules22111829Search in Google Scholar PubMed PubMed Central
47. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers 2018;4:1.10.1038/s41572-018-0001-zSearch in Google Scholar PubMed
48. Swedberg JE, de Veer SJ, Harris JM. Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia. Biol Chem 2010;391:357–74.10.1515/bc.2010.037Search in Google Scholar
49. Sotiropoulou G, Pampalakis G. Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol Sci 2012;33:623–34.10.1016/j.tips.2012.09.005Search in Google Scholar PubMed
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2019-0123).
©2019 Walter de Gruyter GmbH, Berlin/Boston
